Phase I/II Study of the Oral MDM2 Inhibitor DS-3032b in Combination with Low Dose Cytarabine (LDAC), in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
MD Anderson Study Status
Cytarabine, Milademetan Tosylate, Venetoclax
This phase I/II trial studies the side effects and best dose of milademetan tosylate and to see how well it works with cytarabine with or without ventoclax in treating participants with acute myeloid leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Milademetan tosylate and ventoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if giving milademetan tosylate and low-dose cytarabine with or without ventoclax will work better in treating participants with recurrent or refractory acute myeloid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.